anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Abnormal lower limb muscle activity is the most common cause of the alterative pattern of gait in stroke survivors, resulting from spastic and paralytic muscles around the hip, knee, and ankle joints. However, the activity of the major lower limb muscles that control the legs to facilitate walking in stroke patients have not been clearly understood in each subphase of the gait. This study differentiated the characteristics of surface electromyography (sEMG) signals of lower limb muscles during four subphases of gait cycle between stroke patients and healthy subjects. Sixteen chronic stroke patients and sixteen healthy subjects were recruited. All participants completed three walking trials with a self-selected walking speed. The sEMG signals were recorded on the gluteus medius, rectus femoris, long head of biceps femoris, medial gastrocnemius, tibialis anterior, and peroneus longus muscles. The characteristics of sEMG signals were processed and analyzed in the time and frequency features, considering the first double support, single support, second double support, and swing phases of the gait cycle.The stroke patients had altered sEMG characteristics on both paretic and non-paretic sides compared to healthy subjects across the sub-phases of gait cycle for all six muscles. All time domain features of sEMG signal showed that the medial gastrocnemius muscle has the most significant impaired activity (p < 0.05) and affected gait disturbance during all four subphases of the gait cycle. The findings demonstrated that the medial gastrocnemius muscle had impaired activity and was most affected during all four sub-phases of the gait cycle. This indicates that sEMG of medial gastrocnemius muscle can be used to measure the improvement of gait rehabilitation.
The present invention provides a medicament for treating fractures, which relates to a traditional Chinese medicine preparation for treating fractures. The present invention is developed mainly for solving the problems that the existing medicament for treating fractures has poor curative effect and long treatment course. The present invention comprises the raw materials in the formula: frankincense, myrrh, ground beetle, angelica, Chinese thorowax root, eucommia bark, sanchi, keel, amber, rhizoma drynariae, saffron crocus, ephedra herb, borneol, twotooth achyranthes root, cinnabar, cassia twig, radix et rhizoma rhei from sichuan of china, radix dipsaci from sichuan of china, nuxvomica, red peony root, etc. The present invention has the advantages of good curative effect for treating fractures, rapid healing and no toxic side effect. Fractures can be healed generally in a treatment course. Serious fractures can be healed in two or three treatment courses. Compared with the existing medicament for treating fractures, the treatment time of the present invention for treating fractures can be shortened for more than one half.
Fabry disease is an X-linked lysosomal storage disorder which results from reduced activity of the enzyme α-galactosidase A. This reduced enzyme activity results in accumulation of globotriaosylceramide (GL-3), which causes disturbances in multiple organ systems. Patients often complain of acroparesthesia, caused by small-fiber neuropathy. Limited information is available regarding effective treatments for small-fiber neuropathic pain in Fabry disease, and no standard-of-care has yet been established. Opioid analgesics are often used because of their pharmacokinetic properties. While effective, the use of opioids has complications such as constipation, physical dependence and addiction. The purpose of this study is to determine efficacy of gabapentin vs. placebo at controlling peripheral neuropathic pain and reducing the use of opioid analgesics. The investigators are conducting a randomized, double-blind, placebo controlled, single center, cross-over study. The primary endpoint is percent reduction in hydrocodone-acetaminophen use.
If the patient is eligible for study inclusion, the last symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via the video-call and triage the patient.
Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following the long-term administration of ICS, including fluticasone propionate, a component of Fluticasone Propionate/Salmeterol DISKUS. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use Fluticasone Propionate/Salmeterol DISKUS long term.

Effects of treatment with fluticasone propionate/salmeterol DISKUS 500/50 mcg, fluticasone propionate 500 mcg, salmeterol 50 mcg, or placebo on development of cataracts or glaucoma was evaluated in a subset of 658 subjects with COPD in the 3-year survival trial. Ophthalmic examinations were conducted at baseline and at 48, 108, and 158 weeks. Conclusions about cataracts cannot be drawn from this trial because the high incidence of cataracts at baseline (61% to 71%) resulted in an inadequate number of subjects treated with fluticasone propionate/salmeterol DISKUS 500/50 mcg who were eligible and available for evaluation of cataracts at the end of the trial (n = 53). The incidence of newly diagnosed glaucoma was 2% with fluticasone propionate/salmeterol DISKUS 500/50 mcg, 5% with fluticasone propionate, 0% with salmeterol, and 2% with placebo.
The present invention relates to the formulation of ointment resisting human papillomaviruses. The ointment is composed of arsenic trioxide, brucea javanica, red lead, gall, phellodendron bark, borneol, distilled water, monostearin, glycerol, vaseline, stearic acid and triethanolmine. The present invention has the advantages of abundant medicine source and low cost. An effective rate for treating vulva warts by the medicine of the present invention reaches more than 90 %. The medicine is traditional Chinese medicine compound ointment which has no stimulation to normal skins. The ointment has good therapeutic effects on corroding warts, removing stasis, clearing away heat and toxic substances, promoting tissue regeneration and treating warts in vulvae, vaginas and cervixes, vulva black pathological changes, etc. The causes of pointed condylomas (also called venereal warts or foul warts in Chinese medicine) are HPV infections, and the pointed condylomas belong to sexually transmitted diseases with high morbidity. Acquired immune deficiency syndrome is usually merged with pointed condylomas. National standard medicine for treating the disease on domestic market is little currently, so the present invention can replace foreign relevant medicine for treating the venereal disease.
Active group (AG). The AG (n=15) will play game-based foot and ankle exercises via a mobile application on a tablet. They will be asked to wear a foot sensor that is connected to the tablet during the exercise. They will be asked to play the game for 5-minutes, daily. They will do this in conjunction with wearing a compression garment for a period of 4 weeks.
PURPOSE:To obtain an immunoadsorbent useful for the remedy of malignant tumor and autoimmune disease, by subjecting protein A originated from Staphylococcus aureus Cowan I strain to enzymatic reaction and supporting the obtained fragmented protein A on an inert carrier. CONSTITUTION:Protein A originated from Staphylococcus aureus Cowan I strain is subjected to enzymatic reaction (e.g. with trypsin) and the obtained fragmented protein A is supported on an inert carrier through covalent bond or non-covalent bond to obtain an immunoadsorbent. The plasma, serum or whole blood of a living body is made to contact with the immunoadsorbent and the treated plasma, serum or whole blood is returned to the living body to enable the remedy of malignant tumor, etc. Since fragmented protein A has high bonding capability to Ig, high remedying effect can be attained by the use of even a small amount of the supported protein. There is little allergic reaction because the fragmented protein A has low molecular weight.
PURPOSE:To obtain a remedy effective in quickly curing the abomasum displacement of cattle, by using prifinium bromide as an active component. CONSTITUTION:The objective remedy contains prifinium bromide useful as a parasympatholytic drug as an active component. The remedying effect can be further promoted by using the prifinium bromide in combination with metoclopramide and its salt. The drug is applicable to all kind of cattle (e.g., Japanese cattle, Angus or Holstein) affected with abomasum displacement. It is administered generally as an injection or peroral drug. In the case of using the active components in combination, the mixing ratio is generally 1-10:10-1, preferably 1:1. 0.05-10mg (per 1kg of body weight) of prifinium bromide is administered once a day in the case of single use of prifinium bromide or 0.05-10mg of prifinium bromide and 0.05-10mg of metoclopramide and its salt are simultaneously administered once a day based on 1kg of body weight in the case of combined use of the components.
Primary attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. Naloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose or unusual sensitivity to opioids, including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered intravenously with simultaneous efforts at respiratory resuscitation. Since the duration of action of hydrocodone may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug. In cases where consciousness is impaired it may be inadvisable to perform gastric lavage. If gastric lavage is performed, little drug will likely be recovered if more than an hour has elapsed since ingestion. Ibuprofen is acidic and is excreted in the urine; therefore, it may be beneficial to administer alkali and induce diuresis. In addition to supportive measures the use of oral activated charcoal may help to reduce the absorption and reabsorption of ibuprofen. Dialysis is not likely to be effective for removal of ibuprofen because it is very highly bound to plasma proteins.
Apply a thin film of DIPROLENE Ointment to the affected skin areas once or twice daily.

Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. DIPROLENE Ointment is a super-high-potency topical corticosteroid. Treatment with DIPROLENE Ointment should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis [see Warnings and Precautions (5.1)].

DIPROLENE Ointment should not be used with occlusive dressings unless directed by a physician. 

Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site. 

Avoid contact with eyes. Wash hands after each application. 

DIPROLENE Ointment is for topical use only. It is not for oral, ophthalmic, or intravaginal use.
Compositions that may be taken to prolong the useful life of a enteral feeding tube containing a complete nutritional solution and a 1-10C alkyl paraben (0.05-1.0 wt.%). - ACTIVITY : Antimicrobial; gastrointestinal-gen. A commercial sterile nutrient solution Isosource(RTM) was used as a culture medium for various micro-organisms, with and without 0.1% or methyl or propyl paraben. At 35 [deg]C, the growth of Staphylococcus aureus was slightly less in the presence of paraben but there was no inhibition after 48 hours. Enterobacter cloacae was inhibited by methyl paraben at 35 [deg]C, there being a difference of 0.5 logarithmic unit after 48 hours. Lactobacillus leichmanii was inhibited by both parabens after 48 hours at ambient temperature, and at 35 [deg]C 3-5 logarithmic units less than the controls. Aspergillus niger could not be recovered at all after inoculation into a medium the parabens. Candida albicans was inhibited by propyl paraben and after 7 days showed a logarithmic cycle 2-3 UFC/ml less than the controls, though this difference was less than 2 units after 14 days. - MECHANISM OF ACTION : The presence of the paraben hinders the colonization by micro-organisms in the tube, which lead to blockages and degradation of materials, and so shorten the useful life of the tube.
Hematuria is usually only noticed early in the case of macrohematuria. In around half of affected children, macrohematuria is caused by a urinary tract infection. In all other cases, a careful diagnosis is required. In addition to a detailed medical history, this builds upon a precise examination of the urine (microscopy, quantitative determination of proteinuria [mg albumin/g creatinine in spontaneously voided urine]) and measurement of blood pressure. The work-up usually includes sonography as the primary imaging modality. Invasive diagnostic tests using cystoscopy are only necessary in exceptional cases. If there is evidence of glomerulonephritis, a kidney biopsy may be indicated. Careful attention should be given to persisting microhematuria (> 6 months) and Alport syndrome should be confirmed or ruled out. Heterozygotic Alport syndrome can also be a possible cause of chronic renal failure.
Systems and methods for sourcing participants for a usability study are provided. In some embodiments the systems and methods receive study parameters including the type of study, time-to-fieid of the study, required number of participants, and required participant attributes. Additionally, a set of business rules for the study are received. These business rules may be received from a client, extrapolated from a service contract with a client for which the study is being performed, or generated based on the monitored outcomes of sourcing of previous studies. Next, panel sources for potential participants and pricing data are queried, and a set of the sources are selected based upon the pricing data. Participants are then recei ved from these sources, which are then fielded in the study and monitored for outcomes.
Polyploids arise from whole-genome duplication (WGD) events, which have played important roles in genome evolution across eukaryotes. WGD can increase genome complexity, yield phenotypic novelty, and influence adaptation. Neo-polyploids have been reported to often show seemingly stochastic epigenetic and transcriptional changes, but this leaves open the question whether these changes persist in evolved polyploids. A powerful approach to address this is to compare diploids, neo-polyploids, and evolved polyploids of the same species. Arabidopsis arenosa is a species that allows us to do this-natural diploid and autotetraploid populations exist, while neo-tetraploids can be artificially generated. Here, we use ATAC-seq to assay local chromatin accessibility, and RNA-seq to study gene expression on matched leaf and petal samples from diploid, neo-tetraploid and evolved tetraploid A. arenosa. We found over 8,000 differentially accessible chromatin regions across all samples. These are largely tissue specific and show distinct trends across cytotypes, with roughly 70% arising upon WGD. Interestingly, only a small proportion is associated with expression changes in nearby genes. However, accessibility variation across cytotypes associates strongly with the number of nearby transposable elements. Relatively few genes were differentially expressed upon genome duplication, and ∼60% of these reverted to near-diploid levels in the evolved tetraploid, suggesting that most initial perturbations do not last. Our results provide new insights into how epigenomic and transcriptional mechanisms jointly respond to genome duplication and subsequent evolution of autopolyploids, and importantly, show that one cannot be directly predicted from the other.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ketorolac tromethamine. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ketorolac tromethamine and evaluate the patient immediately.
Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
AIMS: Olfactory receptor 2 (Olfr2) has been identified in a minimum of 30% of vascular macrophages, and its depletion was shown to reduce atherosclerosis progression. Mononuclear phagocytes, including monocytes and macrophages within the vessel wall, are major players in atherosclerosis. Single-cell RNA sequencing studies revealed that atherosclerotic artery walls encompass several monocytes and vascular macrophages, defining at least nine distinct subsets potentially serving diverse functions in disease progression. This study investigates the functional phenotype and ontogeny of Olfr2-expressing vascular macrophages in atherosclerosis.
METHODS AND RESULTS: Olfr2+ macrophages rapidly increase in Apoe-/- mice's aorta when fed a Western diet (WD). Mass cytometry showed that Olfr2+ cells are clustered within the CD64 high population and enriched for CD11c and Ccr2 markers. Olfr2+ macrophages express many pro-inflammatory cytokines, including Il1b, Il6, Il12, and Il23, and chemokines, including Ccl5, Cx3cl1, Cxcl9, and Ccl22. By extracting differentially expressed genes from bulk RNA sequencing (RNA-seq) of Olfr2+ vs. Olfr2- macrophages, we defined a signature that significantly mapped to single-cell data of plaque myeloid cells, including monocytes, subendothelial MacAir, and Trem2Gpnmb foamy macrophages. By adoptive transfer experiments, we identified that Olfr2 competent monocytes from CD45.1Apoe-/-Olfr2+/+ mice transferred into CD45.2Apoe-/-Olfr2-/- recipient mice fed WD for 12 weeks, accumulate in the atherosclerotic aorta wall already at 72 h, and differentiate in macrophages. Olfr2+ macrophages showed significantly increased BrdU incorporation compared to Olfr2- macrophages. Flow cytometry confirmed that at least 50% of aortic Olfr2+ macrophages are positive for BODIPY staining and have increased expression of both tumour necrosis factor and interleukin 6 compared to Olfr2- macrophages. Gene set enrichment analysis of the Olfr2+ macrophage signature revealed a similar enrichment pattern in human atherosclerotic plaques, particularly within foamy/TREM2hi-Mφ and monocytes.
CONCLUSIONS: In summary, we conclude that Olfr2+ macrophages in the aorta originate from monocytes and can accumulate at the early stages of disease progression. These cells can undergo differentiation into MacAir and Trem2Gpnmb foamy macrophages, exhibiting proliferative and pro-inflammatory potentials. This dynamic behaviour positions them as key influencers in shaping the myeloid landscape within the atherosclerotic plaque.
Angiotensin-converting enzyme (ACE) is closely related to cardiometabolic risk factors and atherosclerosis. This study aims to investigate whether the insertion/deletion (I/D) variant of ACE gene impacts cardiometabolic risk factors, premature coronary artery disease (PCAD), and severity of coronary lesions. PubMed, Cochrane Library, Central, CINAHL, and ClinicalTrials.gov were searched until December 22, 2023. 94,270 individuals were included for the analysis. Carriers of DD genotype had higher levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), and waist circumference (WC) than carriers of II or ID genotypes. In addition, carriers of DD genotype were at high risk of PCAD and multiple vessel lesions. The impacts of ACE I/D variant on lipid levels were significant in American individuals but stronger in male individuals. In contrast, the impacts of ACE I/D variant on PCAD and severity of coronary lesions were primarily significant in Caucasian individuals. This study indicates that the ACE I/D variant has a slight but significant impact on cardiometabolic risk factors, PCAD, and severity of coronary lesions. Angiotensin-converting enzyme inhibitors (ACEI) may benefit high-risk populations with ACE DD genotype to prevent PCAD and multiple vessel lesions.PROSPERO registration number: CRD42023426732.
BACKGROUND AND PURPOSE: Retaining partial keloid skin to make cross flaps (keloid-cross-flap surgery) is a modification of the core excision. This study aimed to compare the effectiveness of superficial radiotherapy versus compression therapy after keloid-cross-flap surgery.
MATERIALS AND METHODS: In this prospective cohort study, auricular keloid patients were consecutively screened from January 2019 to December 2021. They underwent keloid-cross-flap surgery and then enter either the superficial radiotherapy or the compression treatment group. The primary outcome was the one-year keloid recurrence rate. Secondary outcomes included: non-completion rate of adjuvant treatment; Patient and Observer Scar Assessment Scale (POSAS) scores and auricular aesthetics scores, evaluated by a four-point Likert scale (1 = poor to 4 = excellent) of non-recurring patients. Propensity score matching (PSM) was used to eliminate potential confounding factors.
RESULTS: 123 patients were included in the superficial radiotherapy group and 128 in the compression treatment group. Non-completion rate was significantly higher in the compression treatment group (17.97 %), while the loss rate was comparable between the two groups. Overall, 13 patients (13.54 %) relapsed in superficial radiotherapy group, while 22 patients (25.58 %) in compression group (p < 0.05). After PSM, 59 patients in each group were analyzed, and the recurrence rate was lower in the superficial radiotherapy group (13.56 %). Of relapse-free patients, no significant difference was found in PSAS scores, OSAS scores or aesthetic scores between the two groups.
CONCLUSION: Keloid-cross-flap surgery could provide favorable morphologic repair of the auricular keloid, and postoperative superficial radiotherapy shows higher compliance and lower recurrence rate comparing to compression treatment.